Original ResearchThe REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension
Under a Creative Commons license
open access
Central Illustration
Key Words
cardiac magnetic resonance
hemodynamics
macitentan
pulmonary arterial hypertension
right ventricle
Abbreviations and Acronyms
6MWD
6-minute walk distance
CMR
cardiac magnetic resonance
ERA
endothelin receptor antagonist
NT-proBNP
N-terminal pro–B-type natriuretic peptide
PAH
pulmonary arterial hypertension
PDE-5i
phosphodiesterase-type 5 inhibitor
PVR
pulmonary vascular resistance
RHC
right heart catheterization
RV
right ventricle
RVEF
right ventricular ejection fraction
RVSV
right ventricular stroke volume
WHO FC
World Health Organization functional class
Cited by (0)
The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
- ∗
Dr. Cottreel's current affiliation is Roche, Switzerland.
- †
Drs. Rosenkranz and Galiè are co-last authors.
© 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.